Celldex Stops Phase 3 Study of Brain Cancer Vaccine

Celldex Therapeutics has pulled the plug on a Phase 3 trial of immunotherapy Rintega in patients with EGFRvIII-positive glioblastoma after a mid-trial analysis showed the candidate fared worse than a control group.

The company said last week that an independent review board concluded that the candidate would not reach its primary endpoint: statistically significant overall survival in patients with minimal residual disease.

Rintega produced a median survival rate of 20.4 months in patients, while those in the control group experienced a rate of 21.1 months, a result that “significantly outperformed expectations.”